11/17/2025
This study features one of our esteemed Maui Derm faculty Johnathan I. Silverberg, MD, PhD and it asked whether starting upadacitinib with flexible escalation outperforms dupilumab in adolescents and adults with moderate-to-severe atopic dermatitis for achieving near complete skin clearance and little to no itch by Week 16.
Jonathan I. Silverberg, MD, PhD and colleagues reported the findings in the British Journal of Dermatology in 2025. The primary endpoint was reached by 19.9 percent with upadacitinib vs 8.9 percent with dupilumab at Week 16, with a key secondary of near clear skin in 40.8 percent vs 22.5 percent and faster itch improvement by Day 2 in post hoc daily tracking.
Safety showed no new signals and remained consistent with expected profiles, with more acne and herpes zoster on upadacitinib and more conjunctivitis and arthralgia on dupilumab. Source: Silverberg et al. (Br J Dermatol, 2025)
Attend the Maui Derm Meetings and Earn CME
Maui Derm Caribbean 2026
Fairmont El San Juan Hotel
San Juan, Puerto Rico
January 7 to 10, 2026
Maui Derm Hawaii 2026
Grand Wailea
Maui, Hawaii
January 25 to 29, 2026
Maui Derm NP+PA Summer 2026
The Broadmoor
Colorado Springs, Colorado
June 24 to 27, 2026
Maui Derm NP+PA Fall 2026
The Greenbrier
White Sulfur Springs, WV
September 16 to 19, 2026